Virtual Library

Start Your Search

Junhui Ye

Author of

  • +

    EP1.14 - Targeted Therapy (ID 204)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Targeted Therapy
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.14-45 - ROS1-ADGRG6: A Novel ROS1 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Crizotinib (ID 96)

      08:00 - 18:00  |  Author(s): Junhui Ye

      • Abstract


      ROS1 rearrangements are validated driver genes in non-small cell lung cancer (NSCLC) and have been identified in a small subset (1%-2%) of patients with NSCLC. To date, 18 different fusion genes of ROS1 in NSCLC have been identified. The ALK inhibitor, crizotinib, exhibits therapeutic efficacy against ROS1-rearranged NSCLC. In addition to immunohistochemistry, real-time PCR, and fluorescence in situ hybridization, next-generation sequencing (NGS) technology represents a novel tool for ROS1 detection that covers a wide range of fusion genes.


      A 55-year-old female with stage IV was detected with a novel ROS1 fusion afther treated with gefitinib due to detection of an EGFR mutation (L858R). Histological examination was consistent with lung adenocarcinoma.


      A NGS assay showed that the tumor had a novel ROS1-ADGRG6 rearrangement generated by the fusion of exons of 1-33 of ROS1 on chr6: q22.1 to exons of 2-26 of ADGRG6 on chr6: q24.2. The predicted ROS1-ADGRG6 protein product contained 3075 amino acids comprising the N-terminal amino acids 1-1853 of ROS1 and C-terminal amino acid 1-1222 of ADGRG6. The patient had a favorable tumor response to crizotinib.


      ROS1-ADGRG6 is a novel ROS1 fusion gene in NSCLC detected by NGS and should be considered in ROS1 detection assays.